Jalandhar Online

Sickle Cell Disease (SCD) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

 Breaking News
  • No posts were found

Sickle Cell Disease (SCD) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

July 01
22:00 2021
Sickle Cell Disease (SCD) Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis

DelveInsight Business Research LLP
“Sickle Cell Disease (SCD) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sickle Cell Disease (SCD) Market. The assessment part of the report embraces in-depth Sickle Cell Disease (SCD) commercial assessment and clinical assessment of the Sickle Cell Disease (SCD) pipeline products from the pre-clinical developmental phase to the marketed phase.

Sickle Cell Disease (SCD) Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Sickle Cell Disease (SCD) Market.

The assessment part of the report embraces in-depth Sickle Cell Disease (SCD) commercial assessment and clinical assessment of the Sickle Cell Disease (SCD) pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Sickle Cell Disease (SCD) collaborations, licensing mergers, and acquisition, funding, designations, and other product-related details.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/sickle-cell-disease-pipeline-insight

Sickle Cell Disease (SCD) Overview

Sickle cell disease is a group of inherited red blood cell disorders that affects haemoglobin, the protein that carries oxygen through the body. Normally, red blood cells are disc-shaped and flexible to move easily through the blood vessels. If you have sickle cell disease, your red blood cells are crescent or “sickle” shaped. These cells do not bend and move easily and can block blood flow to the rest of your body.

The blocked blood flow through the body can lead to serious problems, including stroke, eye problems, infections, and episodes of pain, called pain crises.

Sickle Cell Disease (SCD)Emerging Therapy Assessment:

Companies across the globe, such as GBT Therapeutics, Pfizer, AstraZeneca, Ironwood Pharmaceuticals, Imara Therapeutics, and many others, are involved in developing therapies for Sickle Cell Disease. The launch of emerging therapies, such as Rivipansel (Pfizer), IMR-687 (Imara Therapeutics), Ticagrelor (AstraZeneca), and other compelling treatments, are expected to further increase the therapeutic market of Sickle Cell Disease in upcoming years.

Sickle Cell Disease (SCD) Key Companies:

  1. Pfizer

  2. AstraZeneca

  3. Emmaus Life Sciences, Inc.

  4. BlueBird Bio

Sickle Cell Disease (SCD) Therapies covered in the report include:

  1. Rivipansel

  2. Ticagrelor

  3. Endari

  4. LentiGlobin BB305

Report Highlights:

  1. A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Sickle Cell Disease (SCD).

  2. In the coming years, the Sickle Cell Disease (SCD) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world, expanding the size of the market to enable the drug manufacturers to penetrate more into the market.

  3. The companies and academics are working to assess challenges and seek opportunities that could influence Sickle Cell Disease (SCD) Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.

  4. A detailed portfolio of major pharma players who are involved in fueling the Sickle Cell Disease (SCD) treatment market. Several potential therapies for Sickle Cell Disease (SCD) are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Sickle Cell Disease (SCD) market size in the coming years. 

  5. Our in-depth analysis of the Sickle Cell Disease (SCD) pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Table of Contents

  1. Report Introduction

  2. Sickle Cell Disease (SCD)

  3. Sickle Cell Disease (SCD) Current Treatment Patterns

  4. Sickle Cell Disease (SCD) – DelveInsight’s Analytical Perspective

  5. Therapeutic Assessment

  6. Sickle Cell Disease (SCD) Late Stage Products (Phase-III)

  7. Sickle Cell Disease (SCD) Mid Stage Products (Phase-II)

  8. Early Stage Products (Phase-I)

  9. Pre-clinical Products and Discovery Stage Products

  10. Inactive Products

  11. Dormant Products

  12. Sickle Cell Disease (SCD) Discontinued Products

  13. Sickle Cell Disease (SCD) Product Profiles

  14. Sickle Cell Disease (SCD) Key Companies

  15. Sickle Cell Disease (SCD) Key Products

  16. Dormant and Discontinued Products

  17. Sickle Cell Disease (SCD) Unmet Needs

  18. Sickle Cell Disease (SCD) Future Perspectives

  19. Sickle Cell Disease (SCD) Analyst Review 

  20. Appendix

  21. Report Methodology

*The table of contents is not exhaustive; the final content may vary.

Related Reports: 

Sickle Cell Disease (SCD) Market

DelveInsight’s “Sickle Cell Disease (SCD) Market Insights, Epidemiology and Market Forecast – 2030” report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology as well as the Sickle Cell Disease (SCD) Market size and shares analysis for the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Sickle Cell Disease (SCD) Epidemiology

DelveInsight’s Sickle Cell Disease (SCD) – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Sickle Cell Disease (SCD) in the 7MM (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/